Avrobio

About:

Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.

Website: https://avrobio.com/

Twitter/X: avrobio

Top Investors: Cormorant Asset Management, SV Health Investors, Citadel, Atlas Venture, Leerink Partners

Description:

Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure serious debilitating disease. Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy.

Total Funding Amount:

$85M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2015-01-01

Contact Email:

info(AT)avrobio.com

Founders:

Chris Mason, Christopher Paige, Geoff MacKay, Jeffrey Medin

Number of Employees:

101-250

Last Funding Date:

2018-02-01

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai